Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with ocular surface diseases.

In 2023, Brightstar Therapeutics became the first company to offer a long-term solution for patients with impaired ocular healing through the BrightMEM corneal allograft, and we will continue to drive next-generation therapeutics for patients in need.